PCN42 COSTS OF MANAGING ADVERSE EVENTS OF FIRST-LINE THERAPY FOR METASTATIC RENAL CELL CARCINOMA IN MEXICO- BEVACIZUMAB IN COMBINATION WITH INTERFERON-ALPHA-2A COMPARED WITH SUNITINIB
Nov 1, 2010, 00:00 AM
10.1016/S1098-3015(11)71938-6
https://www.valueinhealthjournal.com/article/S1098-3015(11)71938-6/fulltext
Section Title :
RESEARCH POSTER ABSTRACTS
Section Order :
97
First Page :
A258
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(11)71938-6&doi=10.1016/S1098-3015(11)71938-6